Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Subclinical Antibody-mediated Acute Rejection in Kidney Transplant Recipients With the Complement Inhibitor Eculizumab

Next Previous
Trial Profile

Treatment of Subclinical Antibody-mediated Acute Rejection in Kidney Transplant Recipients With the Complement Inhibitor Eculizumab

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms TAMARCIN

Most Recent Events

  • 24 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
  • 15 Jan 2015 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
  • 15 Jan 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top